Date: 16 November 2016
Location: The Nucleus, Chesterford Research Park, Little Chesterford, Cambridge
Hosted by
Domainex
A scientific forum open to all scientists interested in the research and development of new therapeutics in Cambridge and the local area, including scientists at the University, Addenbrooke’s Hospital, pharmaceutical companies, biotechs, CROs, and not-for-profit organisations.
The purpose of Cambridge New Therapeutics Forum (CamNTF) is to promote interactions between scientists in these organisations in order to improve opportunities for biotechnology research and development.
Attendance is free but all attendees must register in advance. Places are limited and early registration will be important to avoid disappointment! Registration closes one week prior to the meeting.
This meeting will feature talks on:
Hypoxia signalling, oxygen-sensing and mitochondria: therapeutic challenges and opportunities
Professor Margaret Ashcroft, Department of Medicine, University of Cambridge
A new anti-thrombotic with no bleeding risk
Dr Karin Conde-Knape, Vice President, Cardiovascular & Metabolism Scientific Innovation, Johnson & Johnson Innovation, London
Location: The Nucleus, Chesterford Research Park, Little Chesterford, Cambridge
Hosted by
Domainex
A scientific forum open to all scientists interested in the research and development of new therapeutics in Cambridge and the local area, including scientists at the University, Addenbrooke’s Hospital, pharmaceutical companies, biotechs, CROs, and not-for-profit organisations.
The purpose of Cambridge New Therapeutics Forum (CamNTF) is to promote interactions between scientists in these organisations in order to improve opportunities for biotechnology research and development.
Attendance is free but all attendees must register in advance. Places are limited and early registration will be important to avoid disappointment! Registration closes one week prior to the meeting.
This meeting will feature talks on:
Hypoxia signalling, oxygen-sensing and mitochondria: therapeutic challenges and opportunities
Professor Margaret Ashcroft, Department of Medicine, University of Cambridge
A new anti-thrombotic with no bleeding risk
Dr Karin Conde-Knape, Vice President, Cardiovascular & Metabolism Scientific Innovation, Johnson & Johnson Innovation, London
|
For more information click here
|
